Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment.

PURPOSE: To evaluate the therapeutic efficacy of Aidi injection combined with megestrol acetate (MA) in patients with endometrial cancer (EC) and to investigate its effects on serum biomarkers, including human epididymis protein 4 (HE4), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125). METHODS: A retrospective analysis was conducted on 120 EC patients treated at Luoyang Central Hospital between January 2023 and January 2024. Patients were categorized into two groups based on their treatment regimen: the MA group (n=60) that received chemotherapy combined with oral MA, and the Aidi group (n=60) that received additional Aidi injection alongside the regimen used in the MA group. Clinical outcomes assessed included overall treatment efficacy, maximum lesion size, survival status, tumor marker levels, serological indicators, and adverse reaction rates (ARR). RESULTS: The Aidi group demonstrated superior outcomes compared to the MA group, with significantly higher objective response rates (ORR) and disease control rates (DCR) (P<0.05). Additionally, the Aidi group demonstrated a greater reduction of maximum lesion diameter (P<0.001), improved quality of life (P<0.001), and lower serum concentrations of HE4, CEA, and CA125 (P<0.001). In addition, levels of connective tissue growth factor (CTGF), angiopoietin-2 (Ang-2), prolactin (PRL), and ARR were significantly reduced (P<0.05). CONCLUSION: Aidi injection combined with MA provided a promising therapeutic strategy for EC. This regimen effectively inhibited tumor progression, improveed quality of life, and decreased serum tumor marker levels (HE4, CEA, and CA125), supporting its potential for broader clinical application.